Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? [electronic resource]
Producer: 20180926Description: 353-355 p. digitalISSN:- 1543-0790
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Chemotherapy, Adjuvant -- methods
- Combined Modality Therapy -- methods
- Gene Expression Regulation, Neoplastic
- Humans
- Imidazoles -- therapeutic use
- Immunotherapy -- methods
- Interferon alpha-2
- Interferon-alpha -- therapeutic use
- Ipilimumab -- therapeutic use
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- Melanoma -- drug therapy
- Nivolumab
- Oximes -- therapeutic use
- Prognosis
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Pyridones -- therapeutic use
- Pyrimidinones -- therapeutic use
- Randomized Controlled Trials as Topic
- Recombinant Proteins -- therapeutic use
- Recurrence
- Skin Neoplasms -- drug therapy
- Survival Analysis
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.